KCPG
ANAC

Kavar Capital Partners Group’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

Kavar Capital Partners Group’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3
Closed – – 516
2015
Q4 		$0 Hold
3
– – ﹤0.01% 558
2015
Q3 		$0 Sell
3
-2
-40% -$261 ﹤0.01% 583
2015
Q2 		$0 Buy
+5
New +$328 ﹤0.01% 557

Other funds holding ANAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Kavar Capital Partners Group's ANAC Position: Q1 2016 in Review

Kavar Capital Partners Group sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q1 2016, closing a stake of 3 shares.

Kavar Capital Partners Group first reported a position in ANAC in Q2 2015 and held it in 3 quarters. The position peaked at $0 in Q4 2015. 199 funds tracked by Wall St. Rank hold ANAC as of Q1 2016.

  • Kavar Capital Partners Group reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q1 2016 after selling out during the quarter.
  • Kavar Capital Partners Group sold 3 ANACOR PHARMACEUTICALS INC COM shares in Q1 2016.
  • Kavar Capital Partners Group first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2015 and held it in 3 quarters.
  • Kavar Capital Partners Group's ANACOR PHARMACEUTICALS INC COM position peaked at $0 in Q4 2015.
  • 199 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q1 2016.

Based on Kavar Capital Partners Group's 13F filing for Q1 2016, filed 13 May 2019.